Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies

Journal of Neurology

Volumn 258, Issue 10, 2011, Pages 1812-1819

  Healy, Brian ^a,b   Chitnis, Tanuja ^a   Engler, David ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Clinical trials; Disease progression; Multiple sclerosis; Sample size calculations

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; THERAPY EFFECT;

ADULT; CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, STATISTICAL; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 80054722792     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6021-1     Document Type: Article

References (28)

1. The IFNB Multiple Sclerosis Study Group 1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology 43 655 661
2. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group 1998 Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis Lancet 352 1498 1504 10.1016/S0140-6736(98)03334-0 (Pubitemid 28512925)
3. Agresti A (2002) Categorical data analysis. Wiley-Interscience, New York
4. P Bajorski J Petkau 1999 Nonparametric two-sample comparisons of changes on ordinal responses J Am Stat Assoc 94 970 978 10.2307/2670011
5. GF Borm J Fransen WA Lemmens 2007 A simple sample size formula for analysis of covariance in randomized clinical trials J Clin Epidemiol 60 1234 1238 17998077 10.1016/j.jclinepi.2007.02.006 (Pubitemid 350064597)
6. MG Brown S Kirby C Skedgel JD Fisk TJ Murray V Bhan IS Sketris 2007 How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 69 1498 1507 17699802 10.1212/01.wnl.0000271884.11129.f3 1:STN:280:DC%2BD2srpslOjsw%3D%3D (Pubitemid 47537856)
7. AJ Coles DA Compston KW Selmaj SL Lake S Moran DH Margolin K Norris PK Tandon 2008 Alemtuzumab vs. interferon beta-1a in early multiple sclerosis N Engl J Med 359 1786 1801 18946064 10.1056/NEJMoa0802670
8. ME Cudkowicz JM Shefner DA Schoenfeld RH Brown Jr H Johnson M Qureshi M Jacobs JD Rothstein SH Appel RM Pascuzzi TD Heiman-Patterson PD Donofrio WS David JA Russell R Tandan EP Pioro KJ Felice J Rosenfeld RN Mandler GM Sachs WG Bradley EM Raynor GD Baquis JM Belsh S Novella J Goldstein J Hulihan 2003 A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis Neurology 61 456 464 12939417 1:CAS:528:DC%2BD3sXmtVemtr4%3D (Pubitemid 37025360)
9. GC Ebers L Heigenhauser M Daumer C Lederer JH Noseworthy 2008 Disability as an outcome in MS clinical trials Neurology 71 624 631 18480462 10.1212/01.wnl.0000313034.46883.16 1:STN:280:DC%2BD1crktVensA%3D%3D
10. SA Gauthier BI Glanz M Mandel HL Weiner 2006 A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study Autoimmun Rev 5 532 536 17027888 10.1016/j.autrev.2006.02. 012 1:CAS:528:DC%2BD28Xht12qtL3E (Pubitemid 44488756)
11. SA Gauthier M Mandel CR Guttmann BI Glanz SJ Khoury RA Betensky HL Weiner 2007 Predicting short-term disability in multiple sclerosis Neurology 68 2059 2065 17562826 10.1212/01.wnl.0000264890.97479.b1 1:STN:280: DC%2BD2szkvFWnsg%3D%3D (Pubitemid 46912123)
12. MP Gorman BC Healy M Polgar-Turcsanyi T Chitnis 2009 Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis Arch Neurol 66 54 59 19139299 10.1001/archneurol.2008.505
13. BC Healy D Engler 2009 Modeling disease-state transition heterogeneity through Bayesian variable selection Stat Med 28 1353 1368 19206077 10.1002/sim.3545
14. LD Jacobs DL Cookfair RA Rudick RM Herndon JR Richert AM Salazar JS Fischer DE Goodkin CV Granger JH Simon JJ Alam DM Bartoszak DN Bourdette J Braiman CM Brownscheidle ME Coats SL Cohan DS Dougherty RP Kinkel MK Mass FE Munschauer 3rd RL Priore PM Pullicino BJ Scherokman RH Whitham, et al. 1996 Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39 285 294 8602746 10.1002/ana.410390304 1:CAS:528:DyaK28XisFyrsLY%3D (Pubitemid 26100751)
15. KP Johnson BR Brooks JA Cohen CC Ford J Goldstein RP Lisak LW Myers HS Panitch JW Rose RB Schiffer T Vollmer LP Weiner JS Wolinsky 2001 Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995 Neurology 57 S16 S24 11902590 1:STN:280:DC%2BD387mvF2qsQ%3D%3D
16. JF Kurtzke 1986 Neuroepidemiology. Part II: assessment of therapeutic trials Ann Neurol 19 311 319 3707082 10.1002/ana.410190402 1:STN:280: DyaL283htlyisg%3D%3D (Pubitemid 16109862)
17. JF Kurtzke 1983 Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1444 1452 6685237 1:STN:280:DyaL2c%2FktValsQ%3D%3D (Pubitemid 14237132)
18. DK Li DW Paty 1999 Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis Ann Neurol 46 197 206 10443885 10.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P 1:CAS:528:DyaK1MXlsFWnt7Y%3D (Pubitemid 29382876)
19. P McCullagh 1980 Regression models for ordinal data J Royal Stat Soc B 42 109 142
20. DW Paty DK Li 1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group Neurology 43 662 667 8469319 1:STN:280: DyaK3s3is1Sqtw%3D%3D (Pubitemid 23121952)
21. CH Polman PW O'Connor E Havrdova M Hutchinson L Kappos DH Miller JT Phillips FD Lublin G Giovannoni A Wajgt M Toal F Lynn MA Panzara AW Sandrock 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 16510744 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D
22. RA Rudick WH Stuart PA Calabresi C Confavreux SL Galetta EW Radue FD Lublin B Weinstock-Guttman DR Wynn F Lynn MA Panzara AW Sandrock 2006 Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 911 923 16510745 10.1056/NEJMoa044396 1:CAS:528:DC%2BD28XitVertLw%3D
23. PH van Elteren 1960 On the combination of independent two-sample tests of Wilcoxon Bull Int Stat Inst 37 1 13
24. J Whitehead 1993 Sample size calculations for ordered categorical data Stat Med 12 2257 2271 8134732 10.1002/sim.4780122404 1:STN:280: DyaK2c7ot1Siuw%3D%3D (Pubitemid 24007147)
25. EB Wilson 1927 Probable inference, the law of succession, and statistical inference J Am Stat Assoc 22 209 212 10.2307/2276774
26. JS Wolinsky PA Narayana KP Johnson 2001 United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center Mult Scler 7 33 41 11321192 1:CAS:528:DC%2BD3MXjs1eis74%3D (Pubitemid 32396577)
27. SL Zeger KY Liang 1986 Longitudinal data analysis for discrete and continuous outcomes Biometrics 42 121 130 3719049 10.2307/2531248 1:STN:280:DyaL283ktlGmuw%3D%3D
28. YD Zhao D Rahardja Y Qu 2008 Sample size calculation for the Wilcoxon-Mann-Whitney test adjusting for ties Stat Med 27 462 468 17487941 10.1002/sim.2912 (Pubitemid 351227880)